重组人血小板生成素、地塞米松联合疗法治疗原发性免疫性血小板减少症的疗效及对T淋巴细胞亚群的影响(1)
[摘要] 目的 探討重组人血小板生成素、地塞米松联合疗法治疗原发性免疫性血小板减少症的疗效及对T淋巴细胞亚群的影响。 方法 选取2016年11月～2018年1月我院收治的原发性免疫性血小板减少症30例，依据治疗方法分为观察组与对照组，各15例，两组患者均应用地塞米松疗法，同时观察组联合重组人血小板生成素治疗，治疗后比较两组的临床疗效及两组患者治疗前后外周血T淋巴细胞亚群的变化情况。 结果 对照组治疗后的总有效率为66.7%(10/15)，观察组患者治疗后的总有效率为86.7%(13/15)。两组疗效比较，差异具有统计学意义(P<0.05)，对照组患者治疗后的CD4+水平及CD4+/CD8+明显高于治疗前(P<0.05)，而CD8+治疗前后未见明显变化，观察组治疗后的CD4+水平及CD4+/CD8+明显高于治疗前及对照组，差异具有统计学意义(P<0.05)，而CD8+水平治疗前后未见明显变化。 结论 重组人血小板生成素、地塞米松联合疗法治疗原发性免疫性血小板减少症可以提高临床疗效，提高免疫功能，值得临床广泛推广和应用。
[关键词] 原发性免疫性血小板减少症；重组人血小板生成素；地塞米松；T淋巴细胞
[中图分类号] R558.2 [文献标识码] B [文章编号] 1673-9701(2018)23-0033-03
Effect of recombinant human thrombopoietin combined with dexamethasone on primary immune thrombocytopenia and T lymphocyte subsets
ZHU Lingling1 ZHANG Yan1 CHEN Guang2 LI Danhong1
1.Department of Hematology， Hongqi Hospital Affiliated to Mudanjiang Medical College， Mudanjiang 157011， China； 2.Department of Hematology， the Second Affiliated Hospital of Mudanjiang Medical College， Mudanjiang 157011， China
[Abstract] Objective To investigate the effect of recombinant human thrombopoietin combined with dexamethasone in the treatment of primary immune thrombocytopenia and its effect on T lymphocyte subsets. Methods We selected 30 cases of primary immune thrombocytopenia treated in our hospital from November 2016 to January 2018. Participants were divided into observation group and control group according to treatment methods with 15 cases in each group. Both groups were treated with dexamethasone. Dexamethasone combined with recombinant human thrombopoietin was performed in the observation group. The clinical efficacy and the changes of T lymphocyte subsets in peripheral blood were compared before and after treatment in the two groups. Results The total effective rate of the control group after treatment was 66.7%(10/15) and the observation group was 86.7%(13/15). The difference of efficacy between the two groups was statistically significant(P<0.05). CD4+ and CD4+/CD8+ levels after treatment in the control group were significantly higher than before treatment(P<0.05)， but there was no significant change in CD8+. The levels of CD4+ and CD4+/CD8+ after treatment were significantly higher than those before treatment and the control group in the observation group(P<0.05)， while no significant change was observed in CD8+ levels. Conclusion The combination of recombinant human thrombopoietin and dexamethasone in the treatment of primary immune thrombocytopenia can improve the clinical efficacy， immune function， and it is worthy of promotion and application in clinic., 百拇医药(朱玲玲 张彦 陈光)
[关键词] 原发性免疫性血小板减少症；重组人血小板生成素；地塞米松；T淋巴细胞
[中图分类号] R558.2 [文献标识码] B [文章编号] 1673-9701(2018)23-0033-03
Effect of recombinant human thrombopoietin combined with dexamethasone on primary immune thrombocytopenia and T lymphocyte subsets
ZHU Lingling1 ZHANG Yan1 CHEN Guang2 LI Danhong1
1.Department of Hematology， Hongqi Hospital Affiliated to Mudanjiang Medical College， Mudanjiang 157011， China； 2.Department of Hematology， the Second Affiliated Hospital of Mudanjiang Medical College， Mudanjiang 157011， China
[Abstract] Objective To investigate the effect of recombinant human thrombopoietin combined with dexamethasone in the treatment of primary immune thrombocytopenia and its effect on T lymphocyte subsets. Methods We selected 30 cases of primary immune thrombocytopenia treated in our hospital from November 2016 to January 2018. Participants were divided into observation group and control group according to treatment methods with 15 cases in each group. Both groups were treated with dexamethasone. Dexamethasone combined with recombinant human thrombopoietin was performed in the observation group. The clinical efficacy and the changes of T lymphocyte subsets in peripheral blood were compared before and after treatment in the two groups. Results The total effective rate of the control group after treatment was 66.7%(10/15) and the observation group was 86.7%(13/15). The difference of efficacy between the two groups was statistically significant(P<0.05). CD4+ and CD4+/CD8+ levels after treatment in the control group were significantly higher than before treatment(P<0.05)， but there was no significant change in CD8+. The levels of CD4+ and CD4+/CD8+ after treatment were significantly higher than those before treatment and the control group in the observation group(P<0.05)， while no significant change was observed in CD8+ levels. Conclusion The combination of recombinant human thrombopoietin and dexamethasone in the treatment of primary immune thrombocytopenia can improve the clinical efficacy， immune function， and it is worthy of promotion and application in clinic., 百拇医药(朱玲玲 张彦 陈光)